CSL Ltd (ASX:CSL), a leading global biotechnology company, has seen its share price increase by 8.3% since the start of 2024. CSL is known for its innovative medicines that address serious medical conditions and contribute to public health. The company operates through three main divisions:
- CSL Behring: Specializes in blood plasma products.
- CSL Seqirus: Focuses on flu-related products and pandemic services.
- CSL Vifor: Provides treatments for iron deficiency and kidney care.
CSL’s plasma collection unit is vital for producing life-saving treatments worldwide. The ASX healthcare stock's growth is driven by its emphasis on plasma and blood collections, alongside strategic acquisitions. CSL's performance indicators show a return on invested capital (ROIC) of 10.30% for FY23 and a revenue compound annual growth rate (CAGR) of 8.7% in recent years. These metrics reflect strong financial health and sustainability for this established business.
Washington H. Soul Pattinson (ASX:SOL)
Washington H. Soul Pattinson Ltd, founded in 1903, is a diversified investment company with a portfolio spanning various industries. Major holdings include stakes in TPG Telecom (ASX:TPG), New Hope Group (ASX:NHC), and Brickworks (ASX:BKW). As a family-run investment company, WHSP aims to deliver superior returns through capital growth and increasing dividends.
Currently, WHSP shares are approximately 3% below their 52-week high. The company’s long-standing reputation and diversified portfolio make it a notable candidate for investors looking for stability and growth.
For CSL Ltd, the current dividend yield stands at around 1.16%, slightly below its 5-year average of 1.24%. This suggests that CSL shares are trading below their historical average dividend yield, providing potential insights into current valuation levels.
Both CSL and WHSP demonstrate strong performance and stability, making them worthy of consideration for inclusion on investment watchlists in 2024.